
VeraDermics Inc (MANE) Stock Forecast & Price Target
VeraDermics Inc (MANE) Analyst Ratings
Bulls say
Veradermics is a strong investment choice due to its innovative and highly anticipated hair loss treatment, VDPHL01, which has shown positive results in phase 2 trials and is expected to be the first non-hormonal option in 30 years. With estimated launch dates for both males and females and a well-funded plan until 2030, the company has the potential for a significant increase in revenue and success in the aesthetic and dermatological market. Their promising pipeline and focused approach further solidify Veradermics' positioning for future growth in the industry.
Bears say
Veradermics is heavily reliant on the success of one product, VDPHL01, with limited diversity in its pipeline and reliance on third parties for key aspects of operations. With the competitive market for hair loss treatments and the uncertainty of FDA approval, the company's stock may be subject to significant volatility and downside risk. Considering the company's lack of diversification and reliance on a single product, combined with the potential challenges and uncertainties in the approval and commercialization process, Veradermics' stock may not be a favorable investment opportunity for a risk-averse investor.
This aggregate rating is based on analysts' research of VeraDermics Inc and is not a guaranteed prediction by Public.com or investment advice.
VeraDermics Inc (MANE) Analyst Forecast & Price Prediction
Start investing in VeraDermics Inc (MANE)
Order type
Buy in
Order amount
Est. shares
0 shares